CliffBio
small molecule

ROCKLATAN

LATANOPROST; NETARSUDIL DIMESYLATE

Loss of exclusivityMarch 2034latest FDA-listed patent expiry
CompanyAlcon →View the full company profile on CliffBio

Drug detail

Brand nameROCKLATAN
Active ingredientLATANOPROST; NETARSUDIL DIMESYLATE
Strength0.005%;EQ 0.02% BASE
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusRX

Listed patents

PatentExpiresType
9993470March 2034substance, product
9931336March 2034substance, product
10588901March 2034substance, product
11020385March 2034use U-1524
11185538March 2034product
11197853March 2034product
9415043March 2034substance
8394826November 2030substance, product
11618748January 2030use U-1524
11028081January 2030use U-1524
10654844January 2030substance, product
10174017January 2030substance, product
10532993July 2026use U-1524
9096569July 2026substance, product
8450344July 2026substance, product
11021456July 2026use U-1524
10882840July 2026use U-1524

More from Alcon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ROCKLATAN patent cliff — loss of exclusivity March 2034 | CliffBio